Contact Information

In a recent press release, Israeli nanotechnology company Piercell proudly announced that Dr. Cyril Cohen, of BIU’s Laboratory of Tumor Immunology and Immunotherapy in the Mina and Everard Goodman Faculty of Life Sciences, will be on its scientific advisory board. Piercell develops therapeutic solutions to a variety of medical problems (PRWeb).

Dr. Cohen, an immuno-cell and gene therapy expert with experience in metastatic melanoma treatment acquired from his post doctoral fellowship at the NIH, will collaborate with Piercell initially on the development of a novel treatment for metastatic melanoma. Piercell aims to integrate its innovative biomolecular delivery device with Dr. Cohen’s cell therapy protocols.

Dr. Cohen’s research is part of a novel approach for the treatment of cancer using immunological cell therapy, namely genetically modifying immune system cells ex-vivo to specifically target and destroy cancer cells in the patient’s body. His current research at BIU is aimed at the exponential enhancement of this treatment’s capabilities.